This invention relates to medical grafting methods and apparatus, and more particularly to methods and apparatus for connecting or fastening tubular bypass grafts.
An example of the possible uses of the invention is a minimally invasive cardiac bypass procedure. This example will be considered in detail, but it will be understood that various aspects of the invention have many other possible uses.
Several procedures are known for revascularizing the human heart in order to treat a patient with one or more occluded coronary arteries. The earliest of these procedures to be developed involves exposing the heart by means of a midline sternotomy. Following surgical exposure of the heart, the patient's aorta and vena cava are connected to a heart/lung machine to sustain vital functions during the procedure. The beating of the heart is stopped to facilitate performance of the procedure. Typically, a suitable blood vessel such as a length of the patient's saphenous (leg) vein is harvested for use as a graft. The graft is used to create a new, uninterrupted channel between a blood source, such as the aorta, and the occluded coronary artery or arteries downstream from the arterial occlusion or occlusions. A variation of the above procedure involves relocating a mammary artery of the patient to a coronary artery.
Although the above-described sternotomy procedures are increasingly successful, the high degree of invasiveness of these procedures and the requirement of these procedures for general anesthesia are significant disadvantages. Indeed, these disadvantages preclude use of sternotomy procedures on many patients.
More recently, less invasive procedures have been developed for revascularizing the heart. An example of these procedures is known as thoracostomy, which involves surgical creation of ports in the patient's chest to obtain access to the thoracic cavity. Specially designed instruments are inserted through the ports to allow the surgeon to revascularize the heart without the trauma of a midline sternotomy. Drugs may be administered to the patient to slow the heart during the procedure. Some thoracostomy procedures involve relocating a mammary artery to a coronary artery to provide a bypass around an occlusion in the coronary artery.
Thoracostomy bypass procedures are less traumatic than sternotomy bypass procedures, but they are still too traumatic for some patients. Also, the number of required bypasses may exceed the number of mammary arteries, thereby rendering thoracostomy procedures inadequate to fully treat many patients.
Another technique for revascularizing the human heart involves gaining access to the thoracic cavity by making incisions between the patient's ribs. This procedure is known as thoracotomy. It is also substantially less traumatic than midline sternotomy, but it is still too traumatic for some patients.
In view of the foregoing, even less traumatic approaches have been developed for revascularizing a patient, as described in Goldsteen et al. U.S. patent application Ser. No. 08/745,618, filed Nov. 7, 1996, and hereby incorporated by reference herein in its entirety. With such approaches, a graft (e.g., of saphenous vein) can be delivered to an operative site in the patient through the patient's existing arteries and veins. The graft is typically inserted between two attachment sites in the patient's existing body organs (e.g., between a site along the patient's aorta and a site along the coronary artery downstream from a coronary artery occlusion).
Thus the above-mentioned Goldsteen et al. reference shows, among other things, methods and apparatus for installing tubular bypass grafts intralumenally. The Goldsteen et al. reference shows methods and apparatus in which each end of the graft site is approached separately and intralumenally, penetrated, and then a longitudinal structure (e.g., element 150 in the Goldsteen et al. reference) is established between the ends of the graft site. This longitudinal structure may extend intralumenally all the way out of the patient's body from both ends of the graft site. The graft is fed into the patient's body intralumenally along the longitudinal structure until it is in the desired position extending from one end of the graft site to the other. Each end of the graft is then secured at a respective end of the graft site and the longitudinal structure is withdrawn from the patient.
Tubular artificial grafts are needed in various medical procedures. For example, such grafts may be needed to replace diseased or damaged sections of natural tubular body tissue such as in the circulatory system, the urinary tract, etc. Or such grafts may be needed to make new connections in natural tubular body tissue systems such as bypass or shunt connections in the circulatory system. In general, an artificial tubular graft may be needed as either a temporary or permanent installation.
Important considerations regarding the use of artificial grafts include ease of use, time required for installation, secureness of installation, and performance after installation. Improvements are constantly sought in all of these areas.
It is therefore an object of this invention to provide improved grafts.
It is therefore a further object of this invention to provide improved methods and apparatus for the connection of grafts, whether natural or artificial.
It is therefore a further object of the invention to provide improved graft structures for use in the repair, replacement, or supplementing of natural body organ structures or tissues, and to provide methods and apparatus for fastening or connecting such graft structures.
It is therefore a further object of this invention to provide improved methods and apparatus for installing medical grafts, whether natural or artificial.
This and other objects of the invention are accomplished in accordance with the principles of the invention by providing apparatus for use as a body tissue graft and methods for securing the graft in a patient comprising a frame structure made of a first elastic material, a covering of a second elastic material on the frame structure, the covering substantially filling openings in the frame structure, and a connector connected to the frame structure. Projections are secured to the connector structure. The projections facilitate attachment of the tubular graft in a patient by securing the graft to the body tissue with which the graft is employed. The connector selectively circumferentially expands and the projections selectively circumferentially expand. This may be done using an inflatable balloon to circumferentially expand the projections and the connector. A restraining member may be provided to restrain the projections in a cone shape so that an end of the graft may be used to open an aperture through a side wall of existing body organ tubing and a portion of the projections may enter the aperture. The connector structures of this invention may be used with artificial grafts having any construction (i.e., other than the frame-and-covering construction mentioned above), and they may also be used with natural body tissue grafts.
Further features of the invention, its nature, and various advantages will be more apparent from the accompanying drawings and the following detailed description of the preferred embodiments.
a is a view similar to
b is a view similar to
a is a simplified elevational view (partly in section) showing another possible alternative construction of portions of the
b is a simplified elevational view of an illustrative embodiment of one component of the apparatus shown in
a is a simplified enlargement of a portion of
a is a simplified longitudinal sectional view showing still another possible alternative construction of portions of the apparatus shown in
a is another view similar to
b is an elevational view taken from the right in
Because the present invention has a number of different applications, each of which may warrant some modifications of such parameters as instrument size and shape, it is believed best to describe certain aspects of the invention with reference to relatively generic schematic drawings. To keep the discussion from becoming too abstract, however, and as an aid to better comprehension and appreciation of the invention, references will frequently be made to specific uses of the invention. Most often these references will be to use of the invention to provide a bypass around an occlusion or obstruction (generically referred to as a narrowing) in a patient's coronary artery, and in particular a bypass from the aorta to a point along the coronary artery which is downstream from the coronary artery narrowing. It is emphasized again, however, that this is only one of many possible applications of the invention.
Assuming that the invention is to be used to provide a bypass from the aorta around a coronary artery narrowing, the procedure may begin by inserting an elongated instrument into the patient's circulatory system so that a distal portion of the instrument extends through the coronary artery narrowing to the vicinity of the point along the artery at which it is desired to make the bypass connection. This is illustrated by
For the illustrative procedure being discussed,
An illustrative construction of tubular structure 120 is shown in more detail in
After instrument 100 is positioned as shown in
The next step in the illustrative procedure being described is preferably to deploy a snare loop 354 (
Once wire 150 is through snare loop 354, snare sheath or lumen 340 is moved distally relative to the snare loop as shown in
After one continuous wire 150 has been established through the patient as described above, the other snare components such as 340 may be withdrawn from the patient by pulling them proximally out of catheter 210. The condition of the apparatus inside the patient is now as shown in
The next phase of the illustrative procedure being described is to install a new length of tubing or graft between regions 24 and 34. The new length of tubing may be either an artificial graft, natural body organ tubing harvested from the patient's body, or a combination of artificial and natural tubing (e.g., natural tubing coaxially inside artificial tubing). In the following discussion it is assumed that the new tubing is to be natural tubing (e.g., a length of the patient's saphenous vein that has been harvested for this purpose) inside an artificial conduit. When such a combination of natural and artificial conduits is used, both conduits can be delivered and installed simultaneously, or the outer artificial conduit can be delivered and installed first, and then the inner natural conduit can be delivered and installed. The following discussion initially assumes that the latter technique is employed.
An illustrative embodiment of an artificial graft 430 is shown in
In accordance with the above-stated assumptions, the next step in the procedure is to use catheter 210 and wire 150 to deliver an artificial conduit such as graft 430 so that it extends between regions 24 and 34. The distal portion of an illustrative assembly 400 for doing this is shown in
Coaxially around tubular member 420 is artificial graft conduit 430. As has been mentioned, an illustrative embodiment of a suitable graft conduit 430 is shown in
In assembly 400 (see again
The portion of assembly 440 at which the proximal end of conduit 430 is located is shown in
To install artificial graft conduit 430 in the patient between regions 24 and 34, assembly 400 is fed into the patient along wire 150 through catheter 210. When tip 412 reaches coronary artery portion 24, tip 412 is threaded into and through the coronary artery wall by rotating tube 410 and therefore tip 412. (Tube 120 may be pulled back slightly at this time to make sure that it does not obstruct tip 412.) The passage of tip 412 through the coronary artery wall opens up the aperture in that wall. After tip 412 passes through the artery wall, that wall seals itself against the outside of the distal portion of conduit delivery tube 440 as shown in
The next step is to push tube 410 and tip 412 distally relative to delivery tube 440, which is held stationary. Conduit 430 is initially moved distally with components 410 and 412. This may be done by inflating balloon 422 so that it engages conduit 430, and then moving tube 420 distally with components 410 and 412. Distal motion of conduit 430 moves struts 436 beyond the distal end of delivery tube 440, thereby allowing the struts 436 to spring out inside coronary artery 20 as shown in
The next step is to pull delivery tube 440 back slightly so that it is withdrawn from coronary artery 20. Then tube 420 is moved distally so that balloon 422 is radially inside the annulus of struts 436. Balloon 442 is then inflated to ensure that struts 436 (and barbs and/or hooks if provided) are firmly set in coronary artery 20. Conditions are now as shown in
The next step is to deflate balloon 422. Then delivery tube 440 is withdrawn proximally until flap 438a (but not flap 438b) is distal of the distal end of the delivery tube. This allows flap 438a to spring radially out as shown in
The next steps are (1) to deflate distal balloon 214, (2) to proximally withdraw catheter 210 a short way, (3) to proximally withdraw tube 420 to press flap 438a against the outer surface of the aorta wall, and (4) to proximally withdraw delivery tube 440 by the amount required to allow flap 438b to spring out against the interior of catheter 210, all as shown in
The next step is to insert the distal portion of delivery tube 440 into the proximal end of conduit 430 as shown in
The next step is to proximally withdraw catheter 210 by the amount required to release flap 438b to spring out against the interior of the wall of aorta 30 as shown in
Artificial graft conduit 430 is now fully established between aorta region 34 and coronary artery region 24. The next steps are therefore to deflate balloon 422 and proximally withdraw tube 420, to collapse tip 412 and proximally withdraw tube 410, and to proximally withdraw delivery tube 440. The proximal end of conduit 430 is now as shown in
As has been mentioned, the illustrative procedure being described assumes that natural body conduit (e.g. a length of the patient's saphenous vein that has been harvested for this purpose) is installed inside artificial conduit 430 after installation of the latter conduit. An illustrative assembly 500 for delivering a length of natural body conduit to installed conduit 430 is shown in
As shown in
Instead of prongs 522, the rings 520 may be provided with fluted or raised structures that grip the graft conduit 430. Instead of balloons 512 being both on the same tube 510, balloon 512a may be on a relatively small first tube, while balloon 512b is on a larger second tube that concentrically surrounds the proximal portion of the first tube. The first and second tubes are axially movable relative to one another, thereby allowing the distance between balloons 512 to be adjusted for grafts 530 of different lengths. An illustrative apparatus of this kind is shown in Goldsteen et al. U.S. patent application Ser. No. 08/839,298, filed Apr. 17, 1997, which is hereby incorporated by reference herein.
Assembly 500 is employed by placing it on wire 150 leading into catheter 210. Assembly 500 is then advanced distally along wire 150 through catheter 210 and then into conduit 430 until the distal end of conduit 530 is adjacent the distal end of conduit 430 and the proximal end of conduit 530 is adjacent the proximal end of conduit 430. The condition of the apparatus at the distal end of assembly 500 is now as shown in
The next step is to proximally withdraw delivery tube 540 so that the distal portion of conduit 530 and distal ring 520a are no longer inside the distal portion of delivery tube 540. Then distal balloon 512a is inflated to circumferentially expand ring 520a and to set prongs 522 through conduit 530 into the surrounding portion of conduit 430 and coronary artery wall portion 24. This provides a completed anastomosis of the distal end of conduit 530 to coronary artery 20.
The next step is to continue to proximally withdraw delivery tube 540 until the proximal end of conduit 530 and proximal ring 520b are no longer inside tube 540 (see
The next step is to deflate balloons 512a and 512b and proximally withdraw tube 510 and delivery tube 540 from the patient via catheter 210. Then wire 150 is withdrawn from the patient, either by pulling it proximally from catheter 210 or by pulling it proximally from elements 110 and 120. Lastly, elements 110, 120, and 210 are all proximally withdrawn from the patient to conclude the procedure. The bypass that is left in the patient is as shown in
The particular uses of the invention that have been described in detail above are only illustrative of many possible uses of the invention. Other examples include same-vessel bypasses in the coronary area and vessel-to-vessel and same-vessel bypasses in other portions of the circulatory system (including neurological areas, renal areas, urological areas, gynecological areas, and peripheral areas generally). A same-vessel bypass is a bypass that extends from one portion of a vessel to another axially spaced portion of the same vessel. In
Another illustrative alternative embodiment of some of the instrumentation shown in
A particularly preferred way of producing a serpentine ring 448 is to start with a short length of thin-walled metal tubing 460 as shown in
As an alternative or addition to reliance on a ring like 448 to resiliently (elastically) self-expand to the full circumferential size desired in a completed graft connection, some or all of the desired circumferential expansion of such a ring may be produced by inflating balloon 422′ or using another selectively radially enlargeable structure inside the ring to plastically deform the ring.
For use in a connector structure that includes struts like 436′, each strut may be connected (e.g., welded) to a peak of the serpentine structure as shown for example in
It will be noted that a ring 448 made as described above in connection with
In the embodiment shown in
Struts 436′ can be forced through tissue such as the wall of coronary artery 20 in their initial cone shape. Sufficient pushing force can be applied to the cone of struts 436′ in any of several ways. For example, tube 420′ may be metal (e.g., stainless steel) hypotube which can transmit pushing force to the cone of struts 436′ by inflating balloon 422′ to trap the base of the cone between balloon 422′ and tube 440. Additional pushing force may then also be applied via tube 440 itself.
When a sufficient portion of the height of the cone of struts 436′ is through the coronary artery wall, balloon 422′ is inflated inside the cone as shown in
As shown in
When a sufficient portion of the height of the cone of struts 436′ is through the coronary artery wall, balloon 422′ is inflated inside the cone as shown in
b depicts tube 440 and cone 441 by themselves in order to better show that cone 441 may have a weakened zone 441a extending in the distal direction to help the cone yield to deploy struts 436′ when balloon 422′ is inflated. Weakened zone 441a can be a slit, a score line, a perforation line or any other generally similar structural feature.
Still another illustrative alternative embodiment of some of the instrumentation shown in
After the distal portion of the cone of struts 436″ has been pushed through the wall of coronary artery 20, tube 420″ is shifted proximally relative to the struts 436″ to release the distal end portions of the barbs. This allows struts 436″ to spring radially outward from ring 448 inside coronary artery 20, thereby anchoring the distal end of the graft conduit in the coronary artery. Ring 448 can then be circumferentially expanded to increase the size of the connection between coronary artery 20 and the distal portion of the graft conduit. If desired, each of struts 436″ may be twisted 180° before it enters the distal end of tube 420″. This promotes turning of the hook-like extreme distal end portions of the struts toward the coronary artery wall when the struts are released from tube 420″.
Ring 448 and struts 436″ may be made of any suitable material such as any 300-series stainless steel (e.g., 316L stainless steel). Another material that may be suitable for struts 436″ is nitinol. As in previously described embodiments, the elastic cover 434 that forms part of conduit 430″ preferably extends to regions 430a and 436″.
In
As shown in
Still another illustrative alternative embodiment of some of the instrumentation shown in
An alternative construction of the proximal end of artificial graft conduit 430 is shown in
In the embodiment shown in
The proximal end of conduit 430 is attached to the wall of aorta 30 (after attachment of the distal end to coronary artery 20 as described above in connection with numerous other FIGS.) by proximally retracting delivery tube 440 so that struts 1436 can spring out against the inside of catheter 210 in the vicinity of proximal balloon 212. Then distal balloon 214 is deflated and catheter 210 is retracted proximally so that struts 1436 can spring out against the inside surface of the wall of aorta 30 as is generally shown in
As part of the procedure for connecting the proximal end of conduit 430 to the aorta, it may be desirable to proximally retract the balloon 422/422′/422″ (described above in connection with numerous other FIGS.) to the proximal end of conduit 430 and to there re-inflate the balloon to help hold conduit 430 in place before proximally retracting delivery tube 440. The balloon can be deflated again at any suitable time (e.g., after delivery tube 440 has been proximally retracted). Balloon 422/422′/422″ may additionally or alternatively be inflated during proximal retraction of catheter 210. This may help ensure that struts 1436 are fully and properly deployed and that the connection of conduit 430 to aorta 30 is properly molded. If a ring similar to ring 448 is part of the proximal conduit connection, inflation of balloon 422/422′/422″ may be used to circumferentially expand that ring as part of the process of connecting conduit 430 to the aorta.
Possible refinements of a proximal connector of the general type shown in
As in previous embodiments, the structure shown in
In the embodiment shown in
The embodiment shown in
The struts 436a of distal connector 449a extend in the distal direction from ring 448a and are initially restrained into a cone shape by a release wire 465 as shown in
As used herein, references to a patient's existing body organ tubing or the like include both natural and previously installed graft tubing (whether natural, artificial, or both). The artificial grafts of this invention may be coated (in the case of tubular grafts, on the inside and/or outside) to still further enhance their bio-utility. Examples of suitable coatings are medicated coatings, hydrophylic coatings, smoothing coatings, collagen coatings, human cell seeding coatings, etc. The above-described preferred porosity of the graft covering helps the graft to retain these coatings. Additional advantages of the artificial grafts of this invention are their elasticity and distensibility, their ability to be deployed through tubes of smaller diameter (after which they automatically return to their full diameter), the possibility of making them modular, their ability to accept natural body organ tubing concentrically inside themselves, their ability to support development of an endothelial layer, their compatibility with MRI procedures, their ability to be made fluoroscopically visible, etc.
It will be understood that the foregoing is only illustrative of the principles of the invention, and that various modifications can be made by those skilled in the art without departing from the scope and spirit of the invention. For example, the order of some steps in the procedures that have been described are not critical and can be changed if desired.
This is a continuation of application Ser. No. 11/060,520, filed Feb. 17, 2005, now U.S. Pat. No. 7,211,095, which is a continuation of application Ser. No. 10/188,699, filed Jul. 2, 2002, now abandoned, which is a continuation of application Ser. No. 09/406,575, filed Sep. 24, 1999, now abandoned, which is a continuation of application Ser. No. 08/839,199, filed Apr. 23, 1997, now U.S. Pat. No. 6,036,702, all of which are hereby incorporated by reference herein in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
2269104 | Hedlund | Jan 1942 | A |
3837345 | Matar | Sep 1974 | A |
3903892 | Komiya | Sep 1975 | A |
3908662 | Razgulov et al. | Sep 1975 | A |
3952742 | Taylor | Apr 1976 | A |
4018228 | Goosen | Apr 1977 | A |
4214587 | Sakura, Jr. | Jul 1980 | A |
4366819 | Kaster | Jan 1983 | A |
4368736 | Kaster | Jan 1983 | A |
4418693 | LeVeen et al. | Dec 1983 | A |
4459252 | MacGregor | Jul 1984 | A |
4503569 | Dotter | Mar 1985 | A |
4592754 | Gupte et al. | Jun 1986 | A |
4605406 | Cahalan et al. | Aug 1986 | A |
4607637 | Berggren et al. | Aug 1986 | A |
4617932 | Kornberg | Oct 1986 | A |
4629458 | Pinchuk | Dec 1986 | A |
4632842 | Karwoski et al. | Dec 1986 | A |
4651733 | Mobin-Uddin | Mar 1987 | A |
4665906 | Jervis | May 1987 | A |
4665918 | Garza et al. | May 1987 | A |
4696300 | Anderson | Sep 1987 | A |
4696308 | Meller et al. | Sep 1987 | A |
4705517 | DiPisa, Jr. | Nov 1987 | A |
4718907 | Karwoski et al. | Jan 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4738740 | Pinchuk et al. | Apr 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4743252 | Martin, Jr. et al. | May 1988 | A |
4748984 | Patel | Jun 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4795458 | Regan | Jan 1989 | A |
4798606 | Pinchuk | Jan 1989 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4892539 | Koch | Jan 1990 | A |
4969890 | Sugita et al. | Nov 1990 | A |
5035702 | Taheri | Jul 1991 | A |
5037377 | Alonso | Aug 1991 | A |
5041082 | Shiber | Aug 1991 | A |
5061245 | Waldvogel | Oct 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5104399 | Lazarus | Apr 1992 | A |
5116360 | Pinchuk et al. | May 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5135467 | Citron | Aug 1992 | A |
5147370 | McNamara et al. | Sep 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5171233 | Amplatz et al. | Dec 1992 | A |
5192294 | Blake, III | Mar 1993 | A |
5201901 | Harada et al. | Apr 1993 | A |
5207695 | Trout, III | May 1993 | A |
5209731 | Sterman et al. | May 1993 | A |
5211658 | Clouse | May 1993 | A |
5211683 | Maginot | May 1993 | A |
5226429 | Kuzmak | Jul 1993 | A |
5234447 | Kaster et al. | Aug 1993 | A |
5250058 | Miller et al. | Oct 1993 | A |
5256150 | Quiachon et al. | Oct 1993 | A |
5275622 | Lazarus et al. | Jan 1994 | A |
5287861 | Wilk | Feb 1994 | A |
5297564 | Love | Mar 1994 | A |
5304220 | Maginot | Apr 1994 | A |
5306240 | Berry | Apr 1994 | A |
5316023 | Palmaz et al. | May 1994 | A |
5334217 | Das | Aug 1994 | A |
5354309 | Schnepp-Pesch et al. | Oct 1994 | A |
5354336 | Kelman et al. | Oct 1994 | A |
5360443 | Barone et al. | Nov 1994 | A |
5366462 | Kaster et al. | Nov 1994 | A |
5366504 | Andersen et al. | Nov 1994 | A |
5387235 | Chuter | Feb 1995 | A |
5395349 | Quiachon et al. | Mar 1995 | A |
5397345 | Lazarus | Mar 1995 | A |
5397355 | Marin et al. | Mar 1995 | A |
5403338 | Milo | Apr 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5419324 | Dillow | May 1995 | A |
5425765 | Tiefenbrun et al. | Jun 1995 | A |
5429144 | Wilk | Jul 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5437288 | Schwartz et al. | Aug 1995 | A |
5441517 | Kensey et al. | Aug 1995 | A |
5443497 | Venbrux | Aug 1995 | A |
5443499 | Schmitt | Aug 1995 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5452733 | Sterman et al. | Sep 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5478354 | Tovey et al. | Dec 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5484418 | Quiachon et al. | Jan 1996 | A |
5486187 | Schenck | Jan 1996 | A |
5489295 | Piplani et al. | Feb 1996 | A |
5496364 | Schmitt | Mar 1996 | A |
5496365 | Sgro | Mar 1996 | A |
5507769 | Marin et al. | Apr 1996 | A |
5509931 | Schmitt | Apr 1996 | A |
5522834 | Fonger et al. | Jun 1996 | A |
5522880 | Barone et al. | Jun 1996 | A |
5522882 | Gaterud et al. | Jun 1996 | A |
5542944 | Bhatta | Aug 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5549663 | Cottone, Jr. | Aug 1996 | A |
5554152 | Aita et al. | Sep 1996 | A |
5562725 | Schmitt et al. | Oct 1996 | A |
5562728 | Lazarus et al. | Oct 1996 | A |
5571172 | Chin | Nov 1996 | A |
5575800 | Gordon | Nov 1996 | A |
5584875 | Duhamel et al. | Dec 1996 | A |
5591197 | Orth et al. | Jan 1997 | A |
5628788 | Pinchuk | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5653747 | Dereume | Aug 1997 | A |
5656013 | Yoon | Aug 1997 | A |
5676670 | Kim | Oct 1997 | A |
5690656 | Cope et al. | Nov 1997 | A |
5695504 | Gifford et al. | Dec 1997 | A |
5702412 | Popov et al. | Dec 1997 | A |
5733308 | Daugherty et al. | Mar 1998 | A |
5755714 | Murphy-Chutorian | May 1998 | A |
5769887 | Brown et al. | Jun 1998 | A |
5797920 | Kim | Aug 1998 | A |
5797933 | Snow et al. | Aug 1998 | A |
5800394 | Yoon et al. | Sep 1998 | A |
5814005 | Barra et al. | Sep 1998 | A |
5817111 | Riza | Oct 1998 | A |
5817113 | Gifford et al. | Oct 1998 | A |
5824002 | Gentelia et al. | Oct 1998 | A |
5830222 | Makower | Nov 1998 | A |
5833698 | Hinchliffe et al. | Nov 1998 | A |
5843164 | Frantzen et al. | Dec 1998 | A |
5843170 | Ahn | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5843176 | Weier | Dec 1998 | A |
5893369 | LeMole | Apr 1999 | A |
5910155 | Ratcliff et al. | Jun 1999 | A |
5931842 | Goldsteen et al. | Aug 1999 | A |
5941908 | Goldsteen et al. | Aug 1999 | A |
5957973 | Quiachon et al. | Sep 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
5976159 | Bolduc et al. | Nov 1999 | A |
5976178 | Goldsteen et al. | Nov 1999 | A |
5993468 | Rygaard | Nov 1999 | A |
6001124 | Bachinski | Dec 1999 | A |
6024763 | Lenker et al. | Feb 2000 | A |
6036702 | Bachinski et al. | Mar 2000 | A |
6068654 | Berg et al. | May 2000 | A |
6074416 | Berg et al. | Jun 2000 | A |
6113612 | Swanson et al. | Sep 2000 | A |
6120432 | Sullivan et al. | Sep 2000 | A |
6136007 | Goldsteen et al. | Oct 2000 | A |
6152937 | Peterson et al. | Nov 2000 | A |
6152945 | Bachinski et al. | Nov 2000 | A |
6190353 | Makower et al. | Feb 2001 | B1 |
6193734 | Bolduc et al. | Feb 2001 | B1 |
6206912 | Goldsteen et al. | Mar 2001 | B1 |
6235054 | Berg et al. | May 2001 | B1 |
6293965 | Berg et al. | Sep 2001 | B1 |
6302905 | Goldsteen et al. | Oct 2001 | B1 |
6309416 | Swanson et al. | Oct 2001 | B1 |
6391036 | Berg et al. | May 2002 | B1 |
6440163 | Swanson et al. | Aug 2002 | B1 |
6451033 | Berg et al. | Sep 2002 | B1 |
6451048 | Berg et al. | Sep 2002 | B1 |
6475222 | Berg et al. | Nov 2002 | B1 |
6508252 | Berg et al. | Jan 2003 | B1 |
6508822 | Peterson et al. | Jan 2003 | B1 |
6511491 | Grudem et al. | Jan 2003 | B2 |
6514196 | Sullivan et al. | Feb 2003 | B1 |
6533812 | Swanson et al. | Mar 2003 | B2 |
6537288 | Vargas et al. | Mar 2003 | B2 |
6582461 | Burmeister et al. | Jun 2003 | B1 |
6589266 | Whitcher et al. | Jul 2003 | B2 |
6599303 | Peterson et al. | Jul 2003 | B1 |
6602263 | Swanson et al. | Aug 2003 | B1 |
6660015 | Berg et al. | Dec 2003 | B1 |
6669256 | Nakayama et al. | Dec 2003 | B2 |
6673085 | Berg | Jan 2004 | B1 |
6702829 | Bachinski et al. | Mar 2004 | B2 |
6726621 | Suon et al. | Apr 2004 | B2 |
6866674 | Galdonik et al. | Mar 2005 | B2 |
6920882 | Berg et al. | Jul 2005 | B2 |
6960219 | Grudem et al. | Nov 2005 | B2 |
20020087046 | Sullivan et al. | Jul 2002 | A1 |
20020087181 | Goldsteen et al. | Jul 2002 | A1 |
20020151913 | Berg et al. | Oct 2002 | A1 |
20020169466 | Peterson et al. | Nov 2002 | A1 |
20020183769 | Swanson et al. | Dec 2002 | A1 |
20020188302 | Berg et al. | Dec 2002 | A1 |
20030060876 | Loshakove et al. | Mar 2003 | A1 |
20030109887 | Galdonik et al. | Jun 2003 | A1 |
20040049221 | Loshakove et al. | Mar 2004 | A1 |
20040092973 | Chanduszko et al. | May 2004 | A1 |
20040092975 | Loshakove et al. | May 2004 | A1 |
20040097973 | Loshakove et al. | May 2004 | A1 |
Number | Date | Country |
---|---|---|
670239 | Jul 1996 | AU |
4404806 | Feb 1995 | DE |
0 539 237 | Apr 1993 | EP |
0 637 454 | Feb 1995 | EP |
0 680 734 | Nov 1995 | EP |
0 684 022 | Nov 1995 | EP |
0 712 614 | May 1996 | EP |
0 732 087 | Sep 1996 | EP |
0 737 453 | Oct 1996 | EP |
0 774 237 | May 1997 | EP |
489 316 | Jul 1938 | GB |
2 269 104 | Feb 1994 | GB |
WO 89-08433 | Sep 1989 | WO |
WO 93-00868 | Jan 1993 | WO |
WO 93-20757 | Oct 1993 | WO |
WO 94-01056 | Jan 1994 | WO |
WO 94-01056 | Jan 1994 | WO |
WO 94-06372 | Mar 1994 | WO |
WO 95-14442 | Jun 1995 | WO |
WO 95-17127 | Jun 1995 | WO |
WO 95-21592 | Aug 1995 | WO |
WO 96-01591 | Jan 1996 | WO |
WO 96-01599 | Jan 1996 | WO |
WO 96-14808 | May 1996 | WO |
WO 96-18361 | Jun 1996 | WO |
WO 96-22745 | Aug 1996 | WO |
WO 96-25897 | Aug 1996 | WO |
WO 97-07741 | Mar 1997 | WO |
WO 97-13463 | Apr 1997 | WO |
WO 97-13471 | Apr 1997 | WO |
WO 97-27893 | Aug 1997 | WO |
WO 97-27897 | Aug 1997 | WO |
WO 97-27898 | Aug 1997 | WO |
WO 98-08456 | Mar 1998 | WO |
WO 98-16161 | Apr 1998 | WO |
WO 98-38939 | Sep 1998 | WO |
WO 99-62408 | Dec 1999 | WO |
WO 99-62415 | Dec 1999 | WO |
WO 00-56223 | Sep 2000 | WO |
WO 00-56226 | Sep 2000 | WO |
WO 00-56227 | Sep 2000 | WO |
WO 00-56228 | Sep 2000 | WO |
WO 01-41623 | Jun 2001 | WO |
WO 01-70090 | Sep 2001 | WO |
WO 01-70119 | Sep 2001 | WO |
WO 02-30172 | Apr 2002 | WO |
WO 02-47532 | Jun 2002 | WO |
WO 03-026475 | Apr 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20070173868 A1 | Jul 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11060520 | Feb 2005 | US |
Child | 11725822 | US | |
Parent | 10188699 | Jul 2002 | US |
Child | 11060520 | US | |
Parent | 09406575 | Sep 1999 | US |
Child | 10188699 | US | |
Parent | 08839199 | Apr 1997 | US |
Child | 09406575 | US |